Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.
The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.
Meg Powell, chief executive officer of TARGET PharmaSolutions, said, "We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner. We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH. This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease."
Breaking News
Boehringer, TARGET Pharma in Strategic NASH Pact
Observational study to incorporate TARGET model of community of stakeholders
10.19.17
Related Breaking News
-
Breaking News | Clinical Trials | CRO News | Drug Development | Information Technology
PAREXEL, Datavant in RWE Alliance
Aims to link healthcare data from a variety of real-world and clinical study data sources to improve drug development09.17.18
-
Analytical Services | Bio News | Collaborations & Alliances | Drug Discovery | Industry News | Information Technology | Laboratory Testing | R&D
FloDesign, Cognate Announce Collaboration
To advance the development of life saving therapeutics by improving manufacturing efficiencies using FloDesign's ACP Platform09.12.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D | Trials & Filings
Boehringer Announces Positive Phase III Results
Confirmed that Cyltezo is equivalent to Humira, with no clinically meaningful differences in efficacy or safety09.12.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Trials & Filings
FDA Grants Amgen & AstraZeneca Breakthrough Therapy Designation
For tezepelumab in patients with severe asthma without an eosinophilic phenotype09.07.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Discovery | Industry News | R&D | Trials & Filings
Gilead, Galapagos Announce Positive Phase 2 Results
In the TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor for the treatment of ankylosing spondylitis09.06.18
-
Clinical Trials | CRO News | Drug Development | Information Technology
-
Bio News | Clinical Trials | Industry News | Promotions & Moves
Altasciences Appoints Clinical Trial Consultant
Dr. William J. Foster, MD, PhD, FRCSC is a practicing retinal physician in Montreal, Canada09.06.18
-
Analytical Services | Bio News | Breaking News | Clinical Trials | Collaborations & Alliances | Industry News | Information Technology | Trials & Filings
CRF's TrialMax Slate Chosen for Phase III Study
The large-scale prostate cancer trial will involve up to 1000 screened patients across 75+ sites and 10+ countries08.30.18
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Information Technology | R&D
Ultimovacs Acquires Immuneed's Immunotherapy Unit
The NOK 50.4mm deal includes a rename of the business unit to Ultimovacs AB08.30.18
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | Drug Development | Industry News
Sirona Biochem Receives $500,000 Milestone from Wanbang
CFDA approves Phase I clinical trial for Sirona's SGLT-2 inhibitor08.29.18
-
Analytical Services | Bio News | Collaborations & Alliances | Industry News | Information Technology
Tjoapack, Veratrak Partner for Blockchain
Will include a number of projects that focus on using the properties of blockchain for collaboration between pharma partners08.29.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Innovate, Amarex Sign Agreement
To provide data management and biostatistics for its planned Phase 3 celiac disease trial08.23.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Rexahn, Merck Partner for Cancer
To evaluate the combination of RX-5902 and Merck’s KEYTRUDA® in a Phase 2 trial in patients with TNBC08.21.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Industry News
Agenus Receives Second Milestone from Merck
Merck initiated a Phase I clinical trial of an antibody candidate discovered by Agenus, sparking a $4M milestone payment08.20.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News
Natera, Fox Chase Cancer Center Partner for Oncology
To assess Signatera™ (Research-Use Only) customized circulating tumor DNA assay for recurrence monitoring of kidney cancer08.20.18
